CA
$30.23
+1.93
(+6.82%)
As of Oct 5, 2026, 3:41 PM EDT · cached
Price history
Caris Life Sciences (CAI) is trading up at $30.23 (+6.82%), as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.
IPO: June 18, 2025 · $21.00 offering · NASDAQ · View IPO details →
Caris Life Sciences revenue & net income history (FY2023–FY2025)
RevenueNet income
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Revenue | $306.1M | $412.3M | $812.0M |
| Growth (year over year) | — | +34.7% | +97.0% |
| Operating income | −$319.6M | −$257.1M | $45.1M |
| Operating margin | −104.4% | −62.4% | 5.6% |
| Net income | −$341.4M | −$281.9M | −$68.1M |
| Net margin | −111.5% | −68.4% | −8.4% |
| EPS (diluted) | −$13.24 | −$10.66 | −$3.22 |
| Balance sheet | |||
| Cash and equivalents | — | $64.0M | $796.3M |
| Total assets | — | $343.7M | $1.13B |
| Total liabilities | — | $620.9M | $548.4M |
| Long-term debt | — | $319.4M | $378.8M |
| Shareholders' equity | −$2.14B | −$2.50B | $577.3M |
| Cash flow | |||
| Operating cash flow | −$276.1M | −$245.2M | $83.2M |
| Capital expenditure | $22.3M | $8.44M | $16.3M |
| Free cash flow | −$298.4M | −$253.6M | $66.9M |
| Share buybacks | $0 | $0 | $113.0K |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $101.6M | $129.9M | $120.9M | $181.4M | $216.8M | $292.9M | $216.2M | $263.7M |
| Growth (year over year) | — | — | +49.9% | +81.3% | +113.4% | +125.4% | +78.8% | +45.4% |
| Operating income | −$60.8M | −$37.0M | −$58.0M | −$18.0M | $32.6M | $88.4M | $5.28M | $26.9M |
| Operating margin | −59.9% | −28.5% | −47.9% | −9.9% | 15.1% | 30.2% | 2.4% | 10.2% |
| Net income | −$67.7M | −$36.9M | −$102.6M | −$71.8M | $24.3M | $82.0M | −$510.0K | −$637.0K |
| Net margin | −66.6% | −28.4% | −84.8% | −39.6% | 11.2% | 28.0% | −0.2% | −0.2% |
| EPS (diluted) | −$2.59 | −$1.73 | −$3.57 | −$7.97 | $0.08 | $8.24 | $0.00 | $0.00 |
| Balance sheet | ||||||||
| Cash and equivalents | — | $64.0M | $31.2M | $718.9M | $753.2M | $796.3M | $819.9M | — |
| Total assets | — | $343.7M | — | $955.1M | $984.6M | $1.13B | $1.16B | $1.23B |
| Total liabilities | — | $620.9M | — | $502.2M | $506.2M | $548.4M | $568.9M | $637.9M |
| Long-term debt | — | $319.4M | — | $373.6M | $376.3M | $378.8M | $381.4M | $393.0M |
| Shareholders' equity | −$2.44B | −$2.50B | −$2.60B | $452.9M | $478.4M | $577.3M | $593.5M | $591.7M |
| Cash flow | ||||||||
| Operating cash flow | −$69.4M | −$38.9M | −$31.3M | $7.29M | $62.4M | $44.8M | $32.9M | $28.5M |
| Capital expenditure | $1.83M | $2.29M | $2.69M | $1.39M | $7.09M | $5.09M | $10.3M | $22.1M |
| Free cash flow | −$71.3M | −$41.2M | −$34.0M | $5.90M | $55.3M | $39.7M | $22.5M | $6.40M |
| Share buybacks | $0 | $0 | $22.0K | $0 | $0 | $91.0K | $0 | $21.4M |
From Caris Life Sciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Caris Life Sciences
- Headquarters
- Irving, Texas From SEC filings, Oct 2026
Recent News (2)
-
Caris Life Sciences Unveils the Next Evolution of Liquid Biopsy with Enhanced Caris Assure Integrated DNA, RNA and Whole-Blood Analysis Provides Deeper Molecular Insights for Precision Oncology IRVING, Texas, Sept. 29, 2026 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading AI TechBio …
-
Caris Life Sciences, ECOG-ACRIN and NRG Oncology Study Demonstrates Multimodal AI Approach to Predict Late Distant Recurrence Risk in HR+ Early Breast Cancer Findings published in Cancer Research Communications highlight potential to inform extended endocrine therapy decisions IRVING, Texas, Aug. 6, 2026 /PRNewswire/ -- Caris Life Sciences® (Caris), a lead…
Other Health Care companies to compare with CAI
- BVS Bioventus Class a Inc
- BWAY BrainsWay
- CABA Cabaletta Bio
- CADL Candel Therapeutics Inc
- CAMP CAMP4 THERAPEUTICS
- CAPR Capricor Therapeutics Inc
- CARL Carlsmed Inc
- CATX Perspective Therapeutics Inc